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CIS protein – is a protein of the SOCS-family and it plays very important role in the 
regulation of the JAK/STAT signalling pathway. This pathway controls immune response and CIS 
can block it by interaction with phosphorilated tyrosine (pTyr)  [1]. The main role in this interaction 
belongs to SH2-domain, which is conservative for the SOCS-family. Therefore, if  we develop the 
small molecule, which can bind with the SH2-domain effectively, we can achieve the enhancing of 
the immune response, especially towards tumors [2]. Moreover, such a molecule can be successfully 
used as a linker in the PROTAC technology, whish supposes the connection of the impaired protein 
to another one that can interact with the ubiquitin ligase. This process leads to the following 
degradation of the impaired protein into the proteasome. In the case of CIS protein this interaction 
can be caused by interaction with elongin B/C, which also plays important role in the interaction of 
CIS with JAK-kinase and influence on the possibility of its binding to pTyr [3]. 
The aims of the study were: 1) to develop the 3D-structure of CIS as it is still remains 
unknown, while the sequence of aminoacids does exist; 2) to analyze interaction of CIS with elongin 
B/C to suggest the way CIS can be influenced by it;  3) to develop the molecule that could 
effectively inhibit the interaction between CIS and pTyr in order to stop the negative regulation of 
the pathway caused by CIS. 
The 3D-structure of CIS was designed with the help of different on-line services (Swiss 
Model, ModWeb, IntFOLD2 etc.) based on the homology modelling.  
Other steps were performed with the help of Maestro tools, ver. 2016-4 (Schrödinger). First, 
we optimized the selected structure by adding absent atoms and editing side chains. Then 
minimizatiom was performed to find the most energetically favorable state of the molecule. To 
analyze the interaction between CIS and elongin B/C we used molecular dynamics. We compared 
dynamics of CIS with the dynamics of complex of CIS and elongin B/C. To develop the inhibitor of 
CIS we detected the binding pocket of pTyr and found out, which aminoacids participated in the 
interaction with pTyr. Then we used the lybrary of different heterocycles to perform the docking and 
to create the small molecule on the basis of the docking results. 
Finally, at the present moment we  have achieved the following results: 1) the 3D-structure of 
CIS was selected; 2) the assesment of the interaction “CIS-elongin B/C” was performed; 3) the 
scaffold of the inhibitor was designed by virtual screening. 
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